Optimization of plasmid-only rescue of highly attenuated and temperature-sensitive respiratory syncytial virus (RSV) vaccine candidates for human trials

Journal of Virological Methods

Volumn 153, Issue 2, 2008, Pages 196-202

  Kaur, J ^a   Tang, R S ^a   Spaete, R R ^a   Schickli, J H ^a  

^a MEDIMMUNE   (United States)

Author keywords

Clinical trials; Electroporation; Human metapneumovirus; Paramyxovirus; Respiratory syncytial virus; Reverse genetics

Indexed keywords

COMPLEMENTARY DNA; ENDOTOXIN; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RIBONUCLEASE A; RNA POLYMERASE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ELECTROPORATION; HELPER VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RISK FACTOR; TEMPERATURE SENSITIVITY; VACCINIA VIRUS; VIRUS INFECTION;

ANIMALS; CERCOPITHECUS AETHIOPS; CLINICAL TRIALS AS TOPIC; DNA-DIRECTED RNA POLYMERASES; ELECTROPORATION; HUMANS; METAPNEUMOVIRUS; PLASMIDS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; TEMPERATURE; TRANSFECTION; VERO CELLS; VIRAL PROTEINS; VIROLOGY;

ANIMALIA; HUMAN METAPNEUMOVIRUS; MAMMALIA; PARAMYXOVIRIDAE; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS; RNA VIRUSES; VACCINIA VIRUS;

EID: 53049100434     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2008.07.012     Document Type: Article

References (42)

1. Boivin G., De Serres G., Cote S., Gilca R., Abed Y., Rochette L., Bergeron M.G., and Dery P. Human metapneumovirus infections in hospitalized children. Emerg. Infect. Dis. 9 (2003) 634-640
2. Buchholz U.J., Finke S., and Conzelmann K.K. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J. Virol. 73 (1999) 251-259
3. Buchholz U.J., Nagashima K., Murphy B.R., and Collins P.L. Live vaccines for human metapneumovirus designed by reverse genetics. Exp. Rev. Vaccines 5 (2006) 695-706
4. CBER, 2001. Letter to sponsors using Vero cells as a cell substrate for investigational vaccines. Center for Biologic Evaluation and Research. http://www.fda.gov/cber/ltr/vero031301.html.
5. Collins P.L., and Crowe J.E. Respiratory Syncytial virus and metapneumovirus. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology (2007), Lippincott Williams & Wilkins, Philadelphia, PA
6. Collins P.L., and Murphy B.R. New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. Proc. Am. Thorac. Soc. 2 (2005) 166-173
7. Collins, P.L., Hill, M.G., Camargo, E., Grosfeld, H., Chanock, R.M., Murphy, B.R., 1995. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5′ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development PNAS, USA. 92 11563-11567.
8. Collins P.L., Whitehead S.S., Bukreyev A., Fearns R., Teng M.N., Juhasz K., Channock R.M., and Murphy B.R. Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics. Adv. Virus Res. 54 (1999) 324-351
9. Connors M., Crowe Jr. J.E., Firestone C.Y., Murphy B.R., and Collins P.L. A cold passaged, attenuated strain of human respiratory syncytial virus contains mutations in the F and L genes. Virology 208 (1995) 478-484
10. Crowe Jr. J.E., Firestone C.Y., Whitehead S.S., Collins P.L., and Murphy B.R. Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single muatation in the polymerase (L) gene. Virus Genes 13 (1996) 269-273
11. Das S.C., Baron M.D., Skinner M.A., and Barrett T. Improved technique for transient expression and negative strand virus rescue using fowlpox T7 recombinant virus in mammalian cells. J. Virol. Methods 89 (2000) 119-127
12. Firestone C.Y., Whitehead S.S., Collins P.L., Murphy B.R., and Crowe Jr. J.E. Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate. Virol. 225 (1996) 419-422
13. Freymuth F., Vabret A., LeGrand L., Eterradossi N., Lafay-Delaire F., Brouard J., and Guillois B. Presence of the new human metapneumovirus in French children with bronchiolitis. Pediatr. Infect. Dis. J. 22 (2003) 92-94
14. Gerna G., Campanini G., Rovida F., Sarashii A., Lilleri D., Paolucci S., Marchi A., Baldanti F., and Revello M.G. Changing circulation rate of human metapneumovirus strains and types among hospitalized pediatric patients during three consecutive winter-spring seasons. Arc. Virol. 150 (2005) 2365-2375
15. Hall C.B. Respiratory syncytial virus and parainfluenza virus. N. Engl. J. Med. 344 (2001) 1917-1927
16. Herfst S., de Graaf M., Schickli J.H., Tang R.S., Kaur J., Yang C.-F., Spaete R.R., Haller A.A., van den Hoogen B.G., Osterhaus A.D.M.E., and Fouchier R.A.M. Recovery of human metapneumovirus genetic lineages A and B from cloned cDNA. J Virol. 78 (2004) 8264-8270
17. Jartti T., van den Hoogen B., Garofalo R.P., Osterhaus A.D.M.E., and Ruuskanen O. Metapneumovirus and acute wheezing in children. Lancet 360 (2002) 1393-1394
18. Jin H., Clarke D., Zhou H.Y.Z., Cheng X., Coelingh K., Bryant M., and Li S. Recombinant human respiratory syncytial virus (RSV) from cDNA and construction of subgroup A and B chimeric RSV. Virology 251 (1998) 206-214
19. Jin H., Cheng X., Zhou H.Z.Y., Li S., and Seddiqui A. Respiratory syncytial virus that lacks open reading frame 2 of the M2 gene (M2-2) has altered growth characteristics and is attenuated in rodents. J. Virol. 74 (2000) 74-82
20. Jin H., Zhou H., Cheng X., Tang R., Munoz M., and Nguyen N. Recombinant respiratory syncytial viruses with deletion in the NS1, NS2, SH and M2-2 genes are attenuated in vitro and in vivo. Virology 273 (2000) 210-218
21. Jin H., Cheng X., Traina-Dorge V.L., Park H.J., Zhou H., Soike K., and Kemble G. Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates. Vaccine 21 (2003) 3647-3652
22. Kapikian A.Z., Mitchell R.H., Chanock R.M., Shvedoff R.A., and Stewart C.E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89 (1969) 405-421
23. Karron R.A., Wright P.F., Crowe Jr. J.E., Clements-Mann M.L., Thompson J., Makhene M., Casey R., and Murphy B.R. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J. Infect. Dis. 176 (1997) 1429-1436
24. Karron R.A., Wright P.F., Belshe R.B., Thumar B., Casey R., Newman F., Polack F.P., Randolph V.B., Deatly A., Hackell J., Gruber W., Murphy B.R., and Collins P.L. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect. Dis. 191 (2005) 1093-1104
25. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., and Jensen K. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89 (1969) 422-434
26. Leung A.K.C., Kellner J.D., and Davies H.D. Respiratory syncytial virus bronchiolitis. J. Natl. Med. Assoc. 97 (2005) 1708-7013
27. Nissen M.D., Siebert D.J., Mackay I.M., Sloots T.P., and Withers S.J. Evidence of human metapneumovirus in Australian children. Med. J. Aust. 176 (2002) 188-190
28. Parks C.L., Lerch R.A., Walpita P., Sidhu M.S., and Udem S.A. Enhanced measles virus cDNA rescue and gene expression after heat shock. J. Virol. 73 (1999) 3560-3566
29. Peret T.C., Boivin G., Li Y., et al. Characterization of human metapneumoviruses isolated from patients in North America. J. Infect. Dis. 185 (2002) 1660-1663
30. Schickli J.H., Kaur J., Ulbrandt N., Spaete R.R., and Tang R.S. An S101P substitution in the putative cleavage motif of the human metapneumovirus fusion protein is a major determinant for trypsin-independent growth in Vero cells and does not alter tissue tropism in hamsters. J. Virol. 79 (2005) 10678-10689
31. Surman S.R., Collins P.L., Murphy B.R., and Skiadopoulos M.H. An improved method for the recovery of recombinant paramyxovirus vaccine candidates suitable for use in human clinical trials. J. Virol. Methods 141 (2007) 30-33
32. Van den Hoogen B.G., Van Doornum G.J., Fockens J.C., Cornelissen J.J., Beyer W.E., De Groot R., Osterhaus A.D., and Fouchier R.A. Prevalence and clinical symptoms of human metapneumovirus infection in hospitalized patients. J. Infect. Dis. 188 (2003) 1571-1577
33. Whitehead S.S., Firestone C.Y., Collins P.L., and Murphy B.R. A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes. Virology 247 (1998) 232-239
34. Whitehead S.S., Bukreyev A., Teng M.N., Firestone C.Y., St Claire M., Elkins W.R., Collins P.L., and Murphy B.R. Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J. Virol. 73 (1999) 3438-3442
35. Whitehead S.S., Firestone C.Y., Karron R.A., Crowe Jr. J.E., Elkins W.R., Collins P.L., and Murphy B.R. Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. J. Virol. 73 (1999) 871-877
36. WHO, 2005. WHO expert committee on biological standardization. World Health Organization. http://www.who.int/biologicals/WHO_TRS_927fulltex.pdf.
37. Williams J.V., Harris P.A., Tollefson S.J., Halburnt-Rush L.L., Pingsterhaus J.M., Edwards K.M., Wright P.F., and Crowe Jr. J.E. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N. Engl. J. Med. 350 (2004) 443-450
38. Williams J.V., Wang C.K., Tang C.-F., Tollefson S.J., House F.X., Heck J.M., Chu M., Brown J.J., Lintao L., Quinto J.D., Chu D., Spaete R.R., Edwards K.M., Wright P.F., and Crowe Jr. J.E. The role of human metapneumovirus in upper respiratory infections in children: a twenty-year experience. J. Infect. Dis. 193 (2006) 387-395
39. Witko W.E., Kotash C.S., Nowak R.M., Johnson J.E., Boutilier L.A.C., Melville K.J., Heron S.G., Clarke D.K., Abramovitz A.S., Hendry R.M., Sidhu M.S., Udem S.A., and Parks C.L. An efficient helper-virus-free method for rescue of recombinant paramyxoviruses and rhabdoviruses from a cell line suitable for vaccine development. J. Virol. Methods 135 (2006) 91-101
40. Wright P.F., Karron R.S., Belshe R.B., et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J. Infect. Dis. 182 (2000) 1331-1342
41. Wright P.F., Karron R.A., Belshe R.B., Shi J.R., Randoph V.B., Collins P.L., O'Shea A.F., Gruber W.C., and Murphy B.R. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine 25 (2007) 7372-7378
42. Yuk I.H., Lin G.B., Ju H., Sifi I., Lam Y., Cortez A., Lieberta D., Berry J.M., and Schwartz R.M. A serum-free Vero production platform for a chimeric virus vaccine candidate. Cytotechnology 51 (2006) 183-192